Trial · NCT03703908
Outcomes14
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | The Number of Subjects With a Reduction in Urine Protein to Creatinine Ratio (UPCR) of at Least 20% | Baseline to week 12 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Achievement of Partial or Complete Remission of UPCR Through Week 12 and Through the End of Treatment | Baseline to week 12 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Proportion of Subjects With Achievement of Complete Remission During the Treatment Period | Baseline to week 52 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Time Taken of Subjects to Achieve Complete Remission During the Treatment Period | Baseline to week 52 | days | NUMBER | |
| SECONDARY | Change From Baseline in Urine Protein:Creatinine Ratio (UPCR) Over Time | Baseline to week 12 and week 52 | Data was not available for all patients at each timepoint | g protein/g creatinine | MEAN |
| SECONDARY | Assessment of Time to and Proportion of Subjects With Achievement of Partial Remission During the Treatment Period | Baseline to week 52 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Time to Rescue Therapy | Baseline to week 52 | Due to the small sample size and early termination of the study, no data could be collected | ||
| SECONDARY | Mean Change From Baseline for eGFR Using the CKD-EPI Cystatin C Equation Over Time | Baseline to Week 12 and Week 52 | Data was not available for all patients at each timepoint | mL/min/1.73m² | MEAN |
| SECONDARY | Mean Change From Baseline for the eGFR CKD-EPI Creatinine Equation Over Time | Baseline to Week 12 and Week 52 | Data was not available for all patients at each timepoint | ml/min/1.73 m² | MEAN |
| SECONDARY | Mean Change From Baseline for eGFR CKD-EPI Creatinine-Cystatin C Equation Over Time | Baseline to Week 12 and Week 52 | Data was not available for all patients at each timepoint | ml/min/1.73 m² | MEAN |
| SECONDARY | Mean Change From Baseline for the MDRD Creatinine Equation Over Time | Baseline to Week 12 and Week 52 | Data was not available for all patients at each timepoint | ml/min/1.73 m² | MEAN |
| SECONDARY | Effect of CCX140-B Treatment on Quality of Life Endpoint SF-36V2 | Baseline to Week 52 | Due to the small sample size and early termination of the study, no data could be collected | ||
| SECONDARY | Effect of CCX140-B Treatment on Quality of Life Endpoint EQ-5D-5L for the Overall Trial | Baseline to Week 12 and Week 52 | Data was not available for all patients at each timepoint. | score on a scale | MEAN |
| SECONDARY | Changes to Laboratory Parameters Related to Renal Function Including Serum Albumin, Creatinine, Cystatin C, Urinary Albumin:Creatinine Ratio, Total 24-hour Protein Excretion During the Trial | Baseline to Day 57 | No data collected |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03703908/outcomes